top of page
CK_cb2000000572.jpg

Company News

최고의 기술력을 기반으로 차세대 분자진단 시장을 앞서 나갑니다.

Search

BioTNS and HK Inno.N Sign MOU for Joint Research on Companion Diagnostic Reagents for New Lung Cancer Drugs

BioTNS announced on the 24th that it has signed a Memorandum of Understanding (MOU) with HK Inno.N to jointly develop a companion diagnostic platform for next-generation non-small cell lung cancer treatments.

Under this agreement, the two companies will collaborate on the research and development of a companion diagnostic platform based on epidermal growth factor receptor (EGFR) inhibitors and digital PCR technology.

BioTNS is developing cancer-focused diagnostic kits based on its proprietary digital PCR platform. The BioTNS digital PCR platform can diagnose genetic mutations in cancer tissues by creating thousands of micro-droplets from a small amount of patient blood. In 2021, BioTNS received approval from the Ministry of Food and Drug Safety for its digital PCR diagnostic equipment, standard reagents, and various consumables. The company explained that with the increasing importance of liquid biopsy in the era of precision medicine, it has successfully localized this core platform and is now focusing on both domestic and international market expansion.

HK Inno.N's allosteric EGFR inhibitor candidate, which is being developed as a new drug for non-small cell lung cancer, works by binding to the allosteric site in the EGFR protein structure, inhibiting EGFR. Last year, it was selected for the "New Drug R&D Ecosystem Construction Research" support project, organized by the National New Drug Development Research Center.

Lee Seung-il, CEO of BioTNS, stated, "Through this joint research with HK Inno.N, we will develop a companion diagnostic platform for non-small cell lung cancer based on BioTNS's digital PCR technology. We plan to expand the scope of diagnostics to include not only companion diagnostics for other cancers but also early diagnosis and monitoring."


Seung-il LEE, CEO of BioTNS (right in the photo), and Bong-tae KIM, Head of the New Drug Research Center at HK Inno.N, are taking a commemorative photo at the MOU signing ceremony.

1 view

Recent Posts

See All

Comments


bottom of page